I am an associate member of the Ludwig Institute for Cancer Research in Oxford, Director of Functional Genomics at the Target Discovery Institute and adjunct Principal Investigator at the Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences. I am also an elected member of the Young Academy of the Austrian Academy of Sciences.
I studied Medical Biology at the University of Utrecht and received my Ph.D. at the Netherlands Cancer Institute in 2005 in the group of René Bernards. During my PhD I performed the first RNAi screen in human cells and worked on the functional annotation of ubiquitin proteases, which since then have emerged as a new drug target class. I was a postdoctoral fellow at The Broad Institute of MIT and Harvard, in the laboratory of Todd Golub and started my own group in 2007 in Vienna at CeMM. There, we discovered the first mechanism of resistance to PI3K/mTOR inhibitors and developed isogenic cell models to discover novel drug-gene interactions.
My research is focused on understanding how drugs work in the complex context of genetic heterogeneity, and the identification of novel drug targets for cancer therapy. To achieve this we employ various functional genomic screening and systems biology approaches.
MSc Medical Biology, Utrecht University
MA Science, Society and Technology Studies, Maastricht University and Autonomous University of Madrid
Ph.D Utrecht University
NWO fellow (2006)
KWF fellow (2007)
Vienna Innovation award (2009)
ERC Starting grant (2012)
Young Academy Member of the Austrian Academy of Sciences (2014)